Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658595 | 0.70 | UHRF1 (0.31) | CYP1A2CYP2A6UHRF1 | |
| SCHEMBL1450435 | 0.68 | CYP1A2 (0.53) | CYP1A2CYP2A6UHRF1CCR1CCR5 | |
| SCHEMBL29045253 | 0.67 | CYP1A2 (0.41) | CYP1A2CYP2A6 | |
| SCHEMBL8160185 | 0.67 | CYP1A2 (0.57) | CYP1A2CYP2A6ABL1CCR1CCR5 | |
| SCHEMBL2320872 | 0.67 | CYP1A2 (0.57) | CYP1A2CYP2A6ABL1CCR1CCR5 | |
| SCHEMBL18266963 | 0.65 | CYP1A2 (0.67) | CYP1A2CYP2A6ABL1UHRF1CCR1 | |
| SCHEMBL8167276 | 0.63 | CYP1A2 (0.52) | CYP1A2CYP2A6ABL1UHRF1CCR1 | |
| SCHEMBL4840796 | 0.63 | CYP2A6 (0.41) | CYP1A2CYP2A6 | |
| SCHEMBL4838237 | 0.63 | CYP2A6 (0.41) | CYP1A2CYP2A6 | |
| SCHEMBL18266965 | 0.62 | CYP1A2 (0.64) | CYP1A2CYP2A6UHRF1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1490340-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080578-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | CYP1A2 464/4885CYP2A6 743/4885ABL1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.